Use of Cyclosporine 0.1% Eye Drops as Prophylactic Treatment in cataract Surgery

To asses ocular discomfort symptoms and signs and inflammatory biomarkers after preoperative topical cyclosporine 0.1% eye drops therapy in high risk elder population after a specific insult such as cataract surgery.

Inclusion Criteria:

• >18 years old
• Postmenopausal women for whom cataract surgery has been scheduled
• Stage N2-3; C1-2 according (Lens Opacities classification System) LOCS
• Willing to sign informed consent and fully participate to all length of the study
• Patients without any previous medical history of ocular and/or systemic inflammatory, autoimmune or auto inflammatory disease
• Patient with no history of ocular surgery
• Patients without any previous or concomitant ocular diseases

Exclusion Criteria:

• Patients under topical or systemic anti- inflammatory drugs Patients with a concomitant diagnosis of glaucoma, or on therapy with antiglaucoma drugs
• Patients on systemic or local therapy with drugs that alter the secretion of the tear film (beta blockers, antidepressants and psychotropics)
• Patients with a history of allergic, congenital, autoimmune systemic diseases
• Patients who have undergone previous eye surgery
• Ocular or peri-ocular malignancies or premalignant conditions
• Active or suspected ocular or peri-ocular infection.
• Complicated Cataract Surgery
• Patients with a positive pregnancy testAllergy or reaction history to study drug
• Patients who participated in a clinical trial in which an investigational drug was administered within 30 days or 5 half-lives of the study drug

1. Screening visit (-30 days)
2. Cataract surgery
3. visit 1 ( 7 days after surgery)
4. visit 2 (15 days after surgery)
5. visit 3 (45 days after surgery),
6. last follow up (90 days after surgery)